Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022139440 - NOVEL RECOMBINANT MYXOMA VIRUS AND USE THEREOF

Publication Number WO/2022/139440
Publication Date 30.06.2022
International Application No. PCT/KR2021/019577
International Filing Date 22.12.2021
IPC
A61K 35/768
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
768Oncolytic viruses not provided for in groups A61K35/761-A61K35/76697
A61P 35/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C12N 7/00 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
A61K 35/76 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
A61K 39/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
CPC
A61K 35/76
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
A61K 35/768
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
768Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
Applicants
  • 바이로큐어 주식회사 VIROCURE, INC. [KR]/[KR]
Inventors
  • 유행준 YOO, Haeng Jun
  • 이연숙 LEE, Yeon Sook
  • 간수크엔크타이반 GANSUKH, Enkhtaivan
  • 김태극 KIM, Tae Geuk
  • 한상경 HAN, Sang Kyoung
Agents
  • 이명진 LEE, Myoung-Jin
Priority Data
10-2020-018082322.12.2020KR
10-2021-003862325.03.2021KR
10-2021-018436021.12.2021KR
Publication Language Korean (ko)
Filing Language Korean (KO)
Designated States
Title
(EN) NOVEL RECOMBINANT MYXOMA VIRUS AND USE THEREOF
(FR) NOUVEAU VIRUS DE LA MYXOMATOSE RECOMBINANT ET SON UTILISATION
(KO) 신규한 재조합 믹소마바이러스 및 이의 용도
Abstract
(EN) The present invention relates to a recombinant Myxoma virus and a use thereof and has been achieved by finding that a recombinant Myxoma virus having multiple anti-cancer genes introduced thereinto can not only exhibit an excellent anticancer effect, but also augment the effect of cancer immunotherapy. The Myxoma virus selected in the present invention, which is an anticancer virus with tumor selectivity, does not cause any infection symptoms except for in rabbits and as such, has the advantage of causing no diseases in humans. Therefore, the Myxoma virus can be administered intravenously at a high dose for a long period of time and activates dendritic cells when administered into the body, thus exhibiting the effect of augmenting immune functions. The present inventors prepared a recombinant Myxoma virus by introducing single or multiple anticancer genes into the genome of Myxoma virus and found that the recombinant virus exhibited more potent anticancer effects than a wild-type virus. Particularly when used in combination with an immune checkpoint inhibitor, the recombinant Myxoma virus according to the present invention was found to have an enhanced anticancer effect of the drug and active anticancer immune functions for a long period of time. Therefore, the recombinant Myxoma virus according to the present invention is expected to be utilized as a novel anticancer therapy for incurable cancer, etc. and as a drug in combination with an immune therapy.
(FR) La présente invention concerne un virus de la myxomatose recombinant et une utilisation de celui-ci et a été obtenue par la découverte qu'un virus de la myxomatose recombinant ayant de multiples gènes anticancéreux introduits dans celui-ci peut non seulement présenter un excellent effet anticancéreux, mais également augmenter l'effet de l'immunothérapie anticancéreuse. Le virus de la myxomatose sélectionné dans la présente invention, qui est un virus anticancéreux ayant une sélectivité tumorale, ne provoque pas de symptômes infectieux excepté chez les lapins et, ainsi, présente l'avantage de ne pas provoquer de maladies chez l'être humain. Par conséquent, le virus de la myxomatose peut être administré par voie intraveineuse à une dose élevée pendant une longue durée et active les cellules dendritiques lorsqu'il est administré dans l'organisme, ce qui a pour effet d'augmenter les fonctions immunitaires. Les présents inventeurs ont préparé un virus de la myxomatose recombinant par introduction de gènes anticancéreux simples ou multiples dans le génome du virus de la myxomatose et ils ont trouvé que le virus recombinant présentait des effets anticancéreux plus puissants qu'un virus de type sauvage. En particulier lorsqu'il est utilisé en combinaison avec un inhibiteur de point de contrôle immunitaire, le virus de la myxomatose recombinant selon la présente invention s'est révélé avoir un effet anticancéreux renforcé du médicament et des fonctions immunitaires anticancéreuses actives pendant une longue durée. Par conséquent, le virus de la myxomatose recombinant selon la présente invention devrait être utilisé en tant que nouvelle thérapie anticancéreuse pour le cancer incurable, etc., et en tant que médicament en combinaison avec une thérapie immunitaire.
(KO) 본 발명은 재조합 믹소마바이러스 및 이의 용도에 관한 것으로서, 다중 항암 유전자가 도입된 재조합 믹소마바이러스가 뛰어난 항암 효과를 가질 뿐만 아니라 면역항암제의 효과를 증강시킬 수 있음을 확인하여 완성된 것이다. 본 발명에서 선택된 믹소마바이러스는 종양 선택성을 가진 항암바이러스로, 토끼 이외의 종에서는 병증을 유발하지 않으므로 사람에게도 질병을 유발하지 않는 장점이 있다. 따라서 믹소마바이러스는 장기간 고용량으로 정맥투여가 가능하며, 체내 투여시 수지상세포 (Dendritic cells)가 활성화되므로 면역 기능을 증강시키는 효과도 있다. 본 발명자들은 믹소마바이러스의 게놈 내에 단일 또는 다중 항암 유전자를 도입하여 재조합 믹소마바이러스를 제조하였으며, 상기 재조합 바이러스는 야생형 바이러스보다 더욱 강력한 항암 효과를 발휘하는 것을 확인하였다. 특히 본 발명에 따른 재조합 믹소마바이러스는 면역관문 억제제와 병용시 약물의 항암 효과를 증진시키고 항암 면역기능을 장기적으로 활성화시킬 수 있음이 확인되었다. 따라서 본 발명에 따른 재조합 믹소마바이러스는 난치암 등을 치료하기 위한 새로운 항암 요법이자 면역항암제의 병용 약물로 활용될 것으로 기대된다.
Latest bibliographic data on file with the International Bureau